A5042535682- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Peptidase Inhibition and Analysis
- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Protease and Inhibitor Mechanisms
- HER2/EGFR in Cancer Research
- Cancer, Hypoxia, and Metabolism
- Blood Coagulation and Thrombosis Mechanisms
- Cancer, Lipids, and Metabolism
- Glycosylation and Glycoproteins Research
- Monoclonal and Polyclonal Antibodies Research
- Bone health and treatments
- Medical Imaging Techniques and Applications
- Neuroendocrine Tumor Research Advances
- Genetic Associations and Epidemiology
- Pancreatic and Hepatic Oncology Research
- Cancer-related Molecular Pathways
- Cell Adhesion Molecules Research
- Lung Cancer Treatments and Mutations
- Cancer Cells and Metastasis
- Radiomics and Machine Learning in Medical Imaging
- Amino Acid Enzymes and Metabolism
- Ferroptosis and cancer prognosis
- Genomics, phytochemicals, and oxidative stress
- RNA modifications and cancer
Mater Research
2019-2025
The University of Queensland
2019-2025
Translational Research Institute
2015-2024
Queensland University of Technology
2015-2021
Centre d'Étude des Pathologies Respiratoires
2013-2021
Prostate Cancer Foundation of Australia
2021
Inserm
2015-2021
Klinikum rechts der Isar
2019
Ecolab (France)
2013
Université de Tours
2011-2012
3D organoid model technologies have led to the development of innovative tools for cancer precision medicine. Yet, gold standard culture system (Matrigel®) lacks ability extensive biophysical manipulation needed various microenvironments and has inherent batch-to-batch variability. Tunable hydrogel matrices provide enhanced capability drug testing in breast (BCa), by better mimicking key physicochemical characteristics this disease’s extracellular matrix. Here, we encapsulated...
There is significant interest in the development of 212Pb-PSMA–based targeted α-therapy for patients with metastatic castration-resistant prostate cancer. A previous phantom study has shown that 212Pb SPECT feasible by imaging 238.6 keV and 75 to 91 γ-emissions produced after β-
In vitro engineering of a bone metastases model allows us to study the effects antiandrogens in advanced prostate cancer.
Emilie Dalloneau1,2, Nadine Baroukh3, Konstantinos Mavridis4, Agnès Maillet1,2, Fabien Gueugnon1,2, Yves Courty1,2, Petit1,2, Thomas Kryza5, Maguy Del Rio6, Serge Guyetant1,2, Diana Carolina Cadena Castaneda3, Christine Dhommée3, Christophe Arnoult3, Andreas Scorilas4, Valérie Gouilleux-Gruart3,7,*, Nathalie Heuzé-Vourc'h1,2,* 1Université François Rabelais, UMR 1100, Tours, France 2INSERM, Centre d'Etude des Pathologies Respiratoires, 3Université Rabelais de CNRS, GICC 7292, 4Department of...
While stromal interactions are essential in cancer adaptation to hormonal therapies, the effects of bone stroma and androgen deprivation on progression poorly understood. Here, we tissue-engineered validated an vitro microtissue model osteoblastic metastases, used it study this microenvironment. The was established by culturing primary human osteoprogenitor cells melt electrowritten polymer scaffolds, leading a mineralized osteoblast-derived containing, 3D setting, viable cells, osteocytic...
Abstract Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer. Experimental Design: CDCP1 expression assessed immunohistochemically in tumors from 423 patients (119 triple-negative cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, lymph node 47 distant metastases). Cell cytotoxicity induced vitro by CDCP1-targeting antibody-drug conjugate (ADC), consisting the human/mouse chimeric antibody ch10D7...
TPS275 Background: Prostate cancer (PC) is the second most common and leading cause of cancer-related death in men. A recent Lancet Commissionarticle predicts a rise PC cases from 1.4 million 2020 to 2.9 by 2040. Despite ten new therapies being available for metastatic decade, survival advantage agents setting castration-resistant prostate (mCRPC) measured months largely due cross-resistance, 5-year approximately 32%. The radioligand therapy 177 Lu-PSMA-617, which uses beta-emitting isotope...
Abstract Introduction: 177Lu-PSMA-617 is the first FDA-approved targeted radioligand therapy (RLT), and in clinical trials, significantly prolonged survival improved quality of life patients with metastatic castration resistant prostate cancer (mCRPC). However, approximately 30% do not respond to treatment most initial responders ultimately relapse. Compared beta-emitter 177Lu, alpha isotope 212Pb may prove be advantageous due its short half-life, high linear energy transfer, efficient...
Abstract Introduction: PSMA-targeted radioligand therapy (RLT) with lutetium-177 (177Lu), a beta-emitter, has been clinically proven to be efficacious for the treatment of prostate cancer (PC). Although emerging clinical data indicate that better efficacy can achieved by alpha-emitters, toxicities associated actinium-225 (225Ac) may limit its broad application especially in early lines treatment. Lead-212 (212Pb), is promising isotope alpha high linear energy transfer, half-life 10.6 hours,...
<p>Supplementary Figures</p>
<div>AbstractPurpose:<p>Receptor CUB domain–containing protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer.</p>Experimental Design:<p>CDCP1 expression assessed immunohistochemically in tumors from 423 patients [119 triple-negative cancer (TNBC); 75 HER2<sup>+</sup>; 229 ER<sup>+</sup>/HER2<sup>−</sup>, including 228 primary lymph node 47 distant metastases). Cell cytotoxicity induced <i>in...
KLK12, a kallikrein peptidase, is thought to take part in the control of angiogenesis. Our analysis secretome endothelial cells (ECs) that had been treated with KLK12 showed converts extracellular matrix- or membrane-bound precursor platelet-derived growth factor B (PDGF-B) into soluble form. Both PDGF-B and vascular A (VEGF-A) induction angiogenesis by coculture model mimics tubule formation. We used cellular approach analyze interplay between PDGF-B, VEGF-A release leads fibroblastmediated...
Abstract Background Tenascins are large glycoproteins found in the extracellular matrix of many embryonic and adult tissues. Tenascin-C is a well-studied biomarker known for its high overexpression stroma most solid cancers. Tenascin-W, least studied member family, highly expressed colon breast tumors gliomas, but not corresponding normal Other have been analyzed. The present study was undertaken to determine whether tenascin-W could serve as cancer-specific protein broad range tumors....
Background: CUB domain-containing protein 1 (CDCP1) is a cell surface receptor regulating key signalling pathways in malignant cells. CDCP1 has been proposed as molecular target to abrogate oncogenic and specifically deliver anti-cancer agents tumors. However, the development of CDCP1-targeting questioned by its frequent proteolytic processing which was thought result shedding extracellular domain limiting targetability. In this study, we investigated relevance targeting context pancreatic...
The 5-year survival for pancreatic ductal adenocarcinoma (PDAC) exceeds 74% if diagnosed at stage I; however, this represents just 12% of resected cases.1Blackford A.L. et al.J Natl Cancer Inst. 2020; 112: 1162-1169Crossref PubMed Scopus (115) Google Scholar Detection cancer stage—or before this, the point high-grade dysplasia (HGD)—represents a significant opportunity to improve survival. Gallium-68–linked fibroblast activation protein inhibitor (68Ga-FAPI) is novel radiotracer used with...
CUB-domain containing protein 1 (CDCP1) is a cancer associated cell surface that amplifies pro-tumorigenic signalling by other receptors including EGFR and HER2.Its potential as target supported studies showing anti-CDCP1 antibodies inhibit migration survival in vitro, tumor growth metastasis vivo.Here we characterize two antibodies, focusing on immuno-conjugates of one these tool to detect ovarian cancer.Methods: A panel lines was examined for expression CDCP1 loss induced 10D7 41-2 using...
Kallikrein-related peptidases (KLKs) are a family of secreted serine proteases, which form network (the KLK activome) with an important role in proteolysis and signaling. In prostate cancer (PCa), increased activity promotes tumor growth metastasis through multiple biochemical pathways, specific quantification tracking changes the activome could contribute to validation KLKs as potential drug targets. Herein we report technology platform based on novel activity-based probes (ABPs) inhibitors...
Kallikrein-related peptidase 7 (KLK7) is a serine that over expressed in ovarian cancer. In vitro functional analyses have suggested KLK7 to play cancer progressive role, although monitoring of expression has contradictory protective role for patients. order help delineate its mechanism action and thereby the roles, information on substrate repertoire crucial. Therefore, this study quantitative proteomics approach–PROtein TOpography Migration Analysis Platform (PROTOMAP)–coupled with SILAC...